… Phase II studies in patients with HF show improved exercise capacity with IL-1 blockade.
Thus, IL-1 blockade is poised to enter the clinical arena as an additional strategy to reduce the …

… for trials of interleukin-1 (IL-1) blockade and particularly anti-IL-1β as an add-on therapy in
human metastatic disease. In animal studies for over 20 years, IL-1 has been demonstrated to …

… gout arthritis, IL-1 blockade can be effective therapy. Three IL-1blockers have been approved:
the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the …

… We tested whether interleukin‐1 blockade with anakinra significantly reduced the area
under the curve for hsCRP (high sensitivity C‐reactive protein) levels during the first 14 days in …

… of evidence which supports the use of IL-1 blockade in the treatment of recurrent pericarditis
as well as provide practical considerations for the use of IL-1 blockade in clinical practice. …

… In common conditions such as heart failure (12,13) and acute gouty arthritis (14–17), IL-1
blockade can be highly effective therapy compared to standards of therapy. Three IL-1 blockers …

… -1 blockade in type 1 diabetes, one with anakinra and the other with canakinumab, are nearing
completion. In this Review, we examine the diseases for which IL-1 blockade … -1 blockade …

… lead to increased IL-1 production and subsequent inflammation [40]. … -1 blockade has been
trialed in patients with FMF over the last decade with promising results. In one study, anti-IL-1 …

… Interleukin 1 induces interleukin 1. 11. Recombinant human interleukin 1 induces interleukin
1 … Warner SJC, Auger KR, Libby P: Human interleukin 1 induces interleukin 1 gene …

… animal studies in which mice lacking the interleukin 1 receptor antagonist (IL-1ra) gene
developed large vessel vasculitis [5], that IL-1 blockade with anakinra could be a therapeutic …